RxDoctor Payments Data

Robert Masci, MD

Cardiovascular Disease · Newton, NJNPI 1730139619

Payments from drug & device makers

$18,892in general payments, 2019–2025

Across 290 payments — averaging $65.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$15K
  • Novartis$762
  • E.r. Squibb & Sons, L.L.C.$671
  • Boehringer Ingelheim$533
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$414
  • Pfizer$224
  • plus $1K from 18 others

What the payments were for

  • Speaking & faculty fees$13,20070%
  • Travel & lodging$1,0906%
  • Food & beverage$4,59424%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,892 in reported general payments places this provider in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$426,703
Medicare patients
1,041
Services billed
4,034

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban448$605,475
EntrestoSacubitril/Valsartan158$202,158
XareltoRivaroxaban84$119,763
Repatha SureclickEvolocumab78$72,314
JardianceEmpagliflozin51$61,730
FarxigaDapagliflozin Propanediol39$43,600
Repatha SyringeEvolocumab31$38,519
Metoprolol Succinate751$14,746
Praluent PenAlirocumab12$10,879
Rosuvastatin Calcium594$8,624
Atorvastatin Calcium604$5,327
Valsartan232$5,041
Carvedilol ErCarvedilol Phosphate11$4,087
Nebivolol Hcl67$4,085
Ezetimibe170$3,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$224$605,475448 claims
NovartisEntresto$762$202,158158 claims
Johnson & JohnsonXarelto$15,017$119,76384 claims
Boehringer IngelheimJardiance$533$61,73051 claims
AstraZenecaFarxiga$79$43,60039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Newton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →